Genmab — Oktober 2017
-
Kræftmidler forlænger ikke livet i syv ud af ti tilfælde
Hovedparten af de kræftmidler, der i perioden 2009-2013 blev godkendt af Det Europæiske Lægemiddelagentur, EMA, øger ikke overlevelsen eller livskvaliteten, viser ny britisk forskning. Men resultaterne bygger på en helt forkert præmis og er derfor irrelevante, mener Lægemiddelstyrelsen.
(medwatch.dk)
-
Vi har vist kun hvad Rachel Gravesen skrev 25/8: The IDMC have yet to take the formal decision on what to do regarding the control group patients and whether they should be offered daratumumab. I would expect this to be something that is considered very soon and a decision taken and verified through the necessary channels ....
-
those looking for a timeline; this was from Danske from the summer - https://www.andelskassen.dk/media/3616/genmab.pdf
-
I think they were
refering to the data we saw Aug 24 http://ir.genmab.com/releasedetail.cfm?ReleaseID=1038151 -
I guess that it is like that when you are the king. Everybody is looking at you, and act on a split second.
-
GENMAB of course E L
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind